Authors: M Hiligsmann O Bruyère JY Reginster
Publish Date: 2009/04/07
Volume: 21, Issue: 1, Pages: 157-
Abstract
A validated Markov microsimulation model with a Belgian healthcare cost perspective was used to assess the cost per qualityadjusted lifeyear QALY of strontium ranelate compared to no treatment on a basis of calcium/vit D supplementation if needed Analyses were performed for women aged 70 75 and 80 years either with a bone mineral density Tscore ≤ −25 SD or with prevalent vertebral fractures The relative risk of fracture during therapy was derived from the Treatment of Peripheral Osteoporosis Study trial over 5 years of treatment Parameter uncertainty was evaluated using both univariate and probabilistic sensitivity analysesStrontium ranelate was costsaving at the age of 80 years in both populations For women with a Tscore ≤ −25 SD the costs per QALY gained of strontium ranelate were respectively €15096 and €6913 at 70 and 75 years of age while these values were €23426 and €9698 for women with prevalent vertebral fractures Sensitivity analyses showed that the results were robust over a wide range of assumptionsMickaël Hiligsmann has received research grant from Amgen Novartis and Servier and lecture fees and reimbursement for attending meetings from Servier Olivier Bruyère has received consulting fees lecture fees and reimbursement for attending meetings from Servier GlaxoSmithKline MSD Theramex Galapagos and Rottarpham JeanYves Reginster has received consulting fees or paid advisory boards from Servier Novartis Negma Ely Lilly Wyeth Amgen GlaxoSmthKline Roche Merkle Nycomed NPS Theramex lecture fees when speaking from Merck Sharp and Dohme Eli Lilly Rottapharm IBSA Genevrier Novartis Servier Roche GlaxoSmithKline Teijin Teva Ebewee Pharma Zodiac Analis Theramex Nycomed and NovoNordisk grant support from Bristol Myers Squibb Merck Sharp Dhome Rottapharm Teva Eli Lilly Novartis Roche GlaxoSmithKline Amgen and Servier
Keywords: